This article first appeared on GuruFocus .
-
Revenue:EUR112.5 million in H1 2026, a nominal decline of 5.1% or 3.3% on a constant currency basis.
-
Adjusted EBIT:EUR7.7 million, compared to EUR8.5 million in the prior year, with an adjusted EBIT margin of 6.9% (down from 7.2%).
-
Reported EBIT:Approximately EUR5.5 million, showing a slight improvement compared to the prior year.
-
Adjusted Net Income:EUR4.1 million, or EUR0.34 per share.
-
Reported IFRS Net Income:EUR2.4 million, or EUR0.20 per share.
-
EBITDA Margin:Improved slightly to 13.9%.
-
Free Cash Flow:EUR23.5 million, compared to a negative free cash flow of EUR14.7 million in the prior year.
-
Operating Cash Flow:EUR29.7 million, compared to a negative figure of EUR5.8 million in the prior year.
-
Systems Revenue:Increased by 15.4% on a constant currency basis to EUR39.7 million.
-
Service Parts and Consumables Revenue:EUR46.1 million, an 11.9% decline on a constant currency basis.
-
Services Revenue:Declined by 7.8% on a constant currency basis.
-
Q2 Adjusted EBIT:Increased by more than 125% to EUR7 million, with the margin improving from 5.4% to 11.9%.
-
Net Debt:Fell to EUR96.7 million, with the net debt to LTM EBITDA ratio improving to 2.9% from 3.3% at the end of 2025.
-
Equity Ratio:Increased to 58.1%.
-
Warning! GuruFocus has detected 5 Warning Signs with XTER:SBS.
-
Is XTER:SBS fairly valued? Test your thesis with our free DCF calculator.
Release Date: August 14, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Stratec SE ( XTER:SBS ) reported a strong Q2 performance, significantly narrowing the year-on-year sales and earnings gap by the end of H1 2026.
-
The system business showed robust growth, with revenues increasing by 15.4% on a constant currency basis, driven by strong demand in immunoassay, molecular diagnostics, and immunohematology.
-
The company demonstrated resilience in its business model, maintaining adjusted EBIT margin close to prior year levels despite weak consumables, showcasing cost discipline.
-
Free cash flow improved dramatically to EUR23.5 million in H1 2026, compared to a negative EUR14.7 million in the prior year, driven by reduced accounts receivable and lower tax payments.
-
Stratec SE ( XTER:SBS ) confirmed its 2026 guidance, expecting a strong year-end business with Q4 contributing 30-33% of annual revenues, and maintained mid-term targets of 6-8% top-line growth and at least 13% adjusted EBIT margin by 2028.
Negative Points
-
Consumables, particularly maintenance parts and spares, were exceptionally weak in H1 2026, with service parts and consumables revenue declining 11.9% on a constant currency basis due to customer inventory optimization.
-
Overall revenue declined by 5.1% (3.3% on a constant currency basis) in H1 2026, impacted by temporary effects and a high comparison base in the development business.
-
The product mix shift away from high-margin service parts and consumables negatively impacted the adjusted EBIT margin, which fell to 6.9% from 7.2% in the prior year.
-
The company faces significant supply chain challenges, including materially increasing lead times and prices for electronics, with no price guarantees from suppliers, posing a risk to margins and delivery.
-
The MDx market remains saturated and flat, with run rates still below pre-COVID levels, and the company expects only a slight recovery, which could limit growth in the near term.
Q & A Highlights
Q: Can you provide more color on the H2 phasing to reach the 10% full-year adjusted EBIT margin target, given H1 came in at just 6.9%? How much of the step-up is covered by firm orders versus forecasts sensitive to customer volatility? A: Marcus Wolfinger (CEO) explained that the margin step-up is driven mainly by operational leverage, as demonstrated in Q2 when the adjusted EBIT increased by over 125% to EUR7 million and the margin improved from 5.4% to 11.9%. He emphasized that as growth returns and production output increases, the margin will follow, with the fourth quarter expected to contribute 30% to 33% of full-year revenues, likely at the top end of that range.
Q: Regarding the weak consumables and maintenance parts business, is this an inventory issue across multiple customers, and is there a risk they could replace these parts with another supplier? A: Marcus Wolfinger (CEO) clarified that this is not limited to one customer but affects several that have undergone M&A activities, where new owners are optimizing service inventories to improve working capital. He noted that while utilization of equipment remains high, sales are under expectations as customers use their warehouses. From a regulatory and risk perspective, he confidently excluded the use of bogus or unapproved spare parts, as the consequences of false negative results would be too severe for customers and end users.
Q: On the supply chain situation, are you seeing similar trends to competitors regarding supplier issues, and could elevated inventory levels help mitigate this? What is your exposure to semiconductor chips? A: Marcus Wolfinger (CEO) stated that while they are not immune, they are better prepared than in the last supply crisis due to layered designs and a special department monitoring long lead time items. He highlighted challenges with pricing, noting that for built-in PCs and electronic components, they can no longer secure prices for future orders. However, new contractual situations with customers allow them to pass on some of these exceptional cost increases.
Q: On the 2026 guidance, you mentioned Q4 accounting for 33% of full-year sales. Does that imply about 10% growth in Q3, or is that too high? A: Marcus Wolfinger (CEO) indicated that Q3 is expected to be in the same ballpark as Q2 in absolute terms. He clarified that the Q4 contribution has been between 30% and 33% over the past years, but their planning model suggests it could be closer to 34% to 35% this year, based on orders already placed and milestone realizations expected in the fourth quarter.
Q: Can you discuss the demand for MDX? The press release mentioned an improvement, but your prepared remarks suggested a flattish, saturated market for the midterm guidance. A: Marcus Wolfinger (CEO) clarified that his statement referred to instruments already in the field. While run rates are going up slightly, they remain below pre-COVID levels. However, the midterm guidance expects a slight recovery driven by new products hitting the market. He noted that the market continues to be saturated with new players, and there are different regional demands, such as more point-of-care dominance in the US and more centralized approaches in other regions.
Q: Regarding lifecycle management, what magnitude of sales is related to this, and what are the lead times for conversion from order to sales? A: Marcus Wolfinger (CEO) explained that product lifecycle management often involves software or replacing functional modules, with shorter revenue cycles. He outlined three measures: last-time buys for products at the tail end of their lifecycle, layered designs for newer products to ease replacement, and redesigns for legacy products, particularly software. He noted that software development and verification are running at or over capacity, driven by regulatory pressures from the FDA on cybersecurity, which is increasingly motivating customers to invest in lifecycle management.
Q: Was some of the strong analyzer growth driven by customer stocking ahead of new product launches, and how is the Natec integration progressing? Have any additional earn-outs been paid? A: Marcus Wolfinger (CEO) confirmed that the analyzer growth was not due to initial stocking ahead of launches but was driven by growing run rates and orders placed from Q4 onward. Regarding Natec, he stated there are no further earn-outs; the sales price is what is in their books. The business is showing progress but is behind initial post-merger integration plans due to volatile market conditions, particularly in the US. However, Natec's US presence makes it a key growth site for the company.
Q: On the CapEx phasing, H1 came in at 5.5% of sales, slightly below the guided corridor of 6.5% to 8.5%. Is this timing or a deliberate slowdown? A: Tanja Buecherl (CFO) stated that they are sticking to the guidance of 6.5% to 8.5% but are closely monitoring business development to avoid pre-investment phases. She indicated that the lower H1 figure reflects careful monitoring, and they will decide on any catch-up in H2 based on how the business develops.
Q: Can you provide details on the other operating income and expenses, which were unusually high and low respectively? A: Tanja Buecherl (CFO) explained that the positive momentum in other operating income was driven by favorable currency effects and R&D grants, especially for the consumable business in Austria and India. This offset the other operating expenses, which were lower than usual in the first half of the year.
Q: Regarding the new forecasting system to limit customers' ability to postpone orders, how is it working and has it improved visibility for H2? A: Marcus Wolfinger (CEO) acknowledged that while the measures have improved efficiency, they have not eliminated volatility entirely. He noted that without these changessuch as longer forecast periods and switching some customers from forecasting to ordering systemsthe situation would be even more challenging. He admitted they are far from perfect but have significantly improved compared to the post-COVID period.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
